3SBio
3SBio Inc is a China-based biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of biological therapies. The company specializes in biopharmaceutical products across core therapeutic areas, including nephrology, oncology, rheumatology, and dermatology. Its primary revenue drivers are sales of proprietary biopharmaceutical drugs such as TPIAO for thrombocytopenia and EPIAO for anemia, alongside dermatological products. The principal end markets serve hospitals, healthcare professionals, and patients throughout mainland China and select export markets. 3SBio maintains a leading domestic market position in China for recombinant protein therapeutics. 3SBio Inc is headquartered in Shenyang, China, and its shares are listed on the Hong Kong Stock Exchange under the ticker 1530.
20 of the funds FundTelligence covers report a position in 3SBio.
- Legal name
- 3SBio Inc
- Sector
- Health Care
- Country
- China
- Funds holding it
- 20
Funds holding 3SBio
- Handelsbanken Asia SMB — Handelsbanken · 0.4 % (full portfolio disclosed, August 2026)
- Nordea Emerging Markets — Nordea Funds · 0.22 % (full portfolio disclosed, September 2026)
- Nordea Emerging Market Equities — Nordea Funds · 0.22 % (full portfolio disclosed, September 2026)
- Mercer Passive Emerging Markets Equity Fund — Mercer · 0.06 % (full portfolio disclosed, December 2025)
- Handelsbanken Asia Tema — Handelsbanken · 0.05 % (full portfolio disclosed, August 2026)
- Lannebo Emerging Markets — Lannebo · 0.04 % (full portfolio disclosed, June 2026)
- KLP AksjeFremvoksende Markeder Indeks — KLP · 0.03 % (full portfolio disclosed, June 2026)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.03 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 20 funds holding it.